52w high/low | ₹2844.4 / ₹1096.25 |
P/E ratio | 77.52 |
Dividend | 0.08 |
ROE | 20.07 |
ROCE | 25.75 |
Face value | 10 |
Book value | ₹1,081.52Cr |
Market capital | ₹21,598.22Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr. '92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr. '94 at a premium of Rs 35 aggregating Rs 5. 69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.